KNSA Q3 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$27M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$282M

Total Liabilities

$30M

Stockholders' Equity

$252M

Cash & Equivalents

$259M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$30M	-$26M	-16.4%
Net Income	-$27M	-$24M	-10.9%